David Geffen School of Medicine at the University of California, Los Angeles, USA.
Clin Infect Dis. 2010 Nov 15;51(10):1201-8. doi: 10.1086/656624. Epub 2010 Oct 18.
Currently, there are 7 approved therapies for chronic hepatitis B virus (HBV) infection, an increase from just 3 agents 5 years ago. This review will focus on the pharmacology, potency, and adverse events associated with immunomodulatory agents and nucleos(t)ide analogues, with an emphasis on targets of therapy within the HBV life cycle. We will also offer guidelines for the use of available anti-HBV agents and review the emerging challenges in hepatitis B management, including HBV drug resistance, its management, and the potential role of combination therapy.
目前，有 7 种批准用于慢性乙型肝炎病毒 (HBV) 感染的治疗方法，这比 5 年前增加了 3 种。本综述将重点介绍免疫调节剂和核苷（酸）类似物的药理学、效力和不良反应，强调 HBV 生命周期内的治疗靶点。我们还将提供可用抗 HBV 药物的使用指南，并回顾乙型肝炎管理中出现的新挑战，包括 HBV 耐药性、管理及其联合治疗的潜在作用。
